Pharmaceutical company accused of limiting competition
The European Commission accuses Novartis and Johnson & Johnson of having agreed to delay the introduction of a generic medicine on the Dutch market. This would be an unacceptable restriction of competition.
The American pharmaceutical company J&J would have paid money to Sandoz (controlled by the Basel giant), to delay the distribution.
Today the Commission sent its criticisms to the two multinationals. This is the second phase of an investigation opened in October 2011, concerning Fentanyl, a more powerful analgesic than morphine.
Thursday 31 January, 3.26pm CSR.ch
Agreement between Novartis and Johnson & Johnson? Brussels is critical
The Basel group will exercise its right of defence
BRUSSELS – The European Commission has sent its criticisms to the pharmaceutical groups Novartis and Johnson & Johnson over the suspicion that the Basel-based group and the American group have reached an agreement to delay the launch of a generic drug on the Dutch market.
This is the second phase of the Commission's investigation, opened in October 2011, concerning Fentanyl, a more potent analgesic than
